Results 61 to 69 of about 1,653 (69)

Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)

Bioorganic and Medicinal Chemistry Letters, 2009
Herbert R Treutlein, Emmanuelle Fantino, Tracy L Nero   +2 more
exaly  

Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure

Journal of the American Academy of Dermatology, 2017
James P Strassner, Brett King, John E Harris   +2 more
exaly  

Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.

Clinical and Experimental Immunology, 2014
K Migita, M Izumi, Y Izumi
exaly  

Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2

SAR and QSAR in Environmental Research, 2014
Om Silakari, Haneesh Jasuja
exaly  

Clinical significance of Janus Kinase inhibitor selectivity.

Rheumatology, 2019
Ernest Choy
exaly  

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib

Journal of the American Academy of Dermatology, 2017
Victor Huang, Deep Joshipura, Alice B Gottlieb   +2 more
exaly  

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F

Journal of Cellular and Molecular Medicine, 2013
René Eulenfeld, Guy Berchem, Iris Behrmann   +2 more
exaly  

Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects

Leukemia and Lymphoma, 2011
Maurilio Ponzoni, Ludovica Riera, Roberto Chiarle   +2 more
exaly  

Janus kinase 3: a novel target for selective transplant immunosupression

Expert Opinion on Therapeutic Targets, 2004
Barry D Kahan
exaly